TII
5.7.2022 11:16:08 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Center (DERC), will organize the upcoming edition of GLOBALEM, a definitive high power electromagnetic (HPEM) conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005033/en/
Set to run from November 13 to 17 at St. Regis Abu Dhabi, the conference marks the first high-profile event DERC is hosting after the launch of its prequalification testing facility at Tawazun Industrial Park in Abu Dhabi dedicated to a specific high-energy physics domain.
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center, will offer expertise as General Chair of the organizing committee of GLOBALEM. Other expert members include Dr. Bill Radasky, of Metatech Corporation USA, and Dr. Nicolas Mora from DERC as joint Technical Program Committee co-chairs, as well as Dr. Felix Vega from DERC, Dr. Lars Ole Fichte from the Helmut-Schmidt University in Hamburg, Germany, and Dr. Jane Lehr, from the University of New Mexico, USA, as conference advisors.
Unpacking the challenges and opportunities that currently exist as well as those evolving everyday in the crucial field of electromagnetics, the conference is set to draw the interest of experts from fields as diverse as pulsed power technologies, high voltage generator, microwaveradiation, covering analytical and numerical modeling as well as experimental validation
All eyes will be trained on the Best Student Paper Award (BSPA), with award recipients receiving a certificate and a cash prize of US$500.
Likewise, the Young Scientist Award (YSA) recognizes a young researcher under 35 who has made innovative contributions in fields related to HPEM. Researchers keen to participate in the contest can nominate themselves during the submission process.
For both awards, the last date for the submission of extended abstracts online is July 1, 2022. Acceptance confirmations and nominations will be completed by August 15, and September 15 is the last date for the final review and submission of full papers and award nominations. Early bird registration is open until September 30, 2022.
Highlighting the significance of the conference for the TII ecosystem and for Abu Dhabi as well, Dr. Kasmi said: “The GLOBALEM conference promises to be a game changer for the region. High Power Electromagnetics is one of those hot areas in focus today for us at DERC, given the varied number of applications and sectors it straddles – from your everyday generators, motors, and transformers, to maglev trains, and astronomy to health care and everything in between. We are even focusing on new innovations that can treat certain types of cancer. Being able to convene so many global experts in Abu Dhabi is unprecedented and is a big deal for TII and the region.”
For more information on the GLOBALEM Conference 2022, and to submit scientific papers please visit: https://globalem2022.com/submission.php
About the Technology Innovation Institute (TII)
The Technology Innovation Institute (TII) is the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), and a leading global scientific research center that focuses on shaping breakthrough solutions and new-age technology capabilities. In working with exceptional talent, universities, research institutions and industry partners from around the world, TII connects an intellectual community and contributes to building a thriving R&D ecosystem that elevates the status of Abu Dhabi and the UAE as a global hub for innovation. For more information, please visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom